☰

Onika T. Murray, Ph.D. - Publications

Affiliations: 
2012 Molecular and Cellular Pharmacology Stony Brook University, Stony Brook, NY, United States 
Area:
Pharmacology, Molecular Biology
Tree Info Similar researchers PubMed Report error

4 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Murray OT, Wong CC, Vrankova K, Rigas B. Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. International Journal of Oncology. 44: 521-9. PMID 24284479 DOI: 10.3892/Ijo.2013.2190  0.569
2012 Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, Alston N, Zhu C, Murray OT, Constantinides PP, Kopelovich L, Rigas B. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. British Journal of Pharmacology. 165: 2152-66. PMID 21955327 DOI: 10.1111/J.1476-5381.2011.01705.X  0.458
2012 Murray OT, Vrankova K, Johnson F, Rigas B. Abstract 4431: NFATc1 silencing increases sensitivity of pancreatic cancer cells to phosphosulindac Cancer Research. 72: 4431-4431. DOI: 10.1158/1538-7445.Am2012-4431  0.559
2009 Zhao W, Mackenzie GG, Murray OT, Zhang Z, Rigas B. Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis. 30: 512-9. PMID 19136474 DOI: 10.1093/Carcin/Bgp015  0.531
Show low-probability matches.